Skip to content

0.5% Pilocarpine in the Treatment of High Hyperopia

0.5% Pilocarpine in the Treatment of High Hyperopia: A Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016564
Enrollment
Unknown
Registered
2018-06-08
Start date
2018-07-02
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperopia

Interventions

Pilocarpine group:Use 0.5% pilocarpine and wear spectacles
Spectacles group:Wear spectacles and use placebo eye drop

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 10 Years

Inclusion criteria

Inclusion criteria: (1) Aged 3-10 years; (2) Cycloplegic refractive diopters>+5.00 D in each eye; (3) Normal intraocular pressure of <21 mmHg; (4) Fully understood the purpose of the clinical trial and willing to sign the informed consent; (5) To be able to complete the follow-up visits according the researchers command and accept examination and instruction.

Exclusion criteria

Exclusion criteria: (1) Severe ocular disease such as iridocyclitispupillary block glaucomasecondary glaucoma with uveitisneovascular glaucoma and retinal detachment; (2) Undergoing other treatment for high hyperopia; (3) With systemic disease can influence vision development, such as diabetes and Downs syndrome; (4) Unable to finish regular follow-up visits; (5) Inability to understand the limitations of treatment; (6) Patients who are over sensitive or with excessive expectation; (7) Other unsuitable situations judged by the researchers.

Design outcomes

Primary

MeasureTime frame
Axial Length;

Secondary

MeasureTime frame
Refractive Diopters;

Countries

China

Contacts

Public ContactDongmei Cui

Zhongshan Ophthalmic Center, Sun Yat-Sen University

sarah72@126.com+86 13143535298

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026